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A spectrophotometric method has been studied for the determination of epsilon aminocaproic acid (EACA) through 
charge transfer (CT) complexation with bromanil (TBBQ). The CT reaction has been carried out at 70 °C of the water bath 
for 30 min in the borax buffer solution. The spectrum obtained for EACA/TBBQ system shows the maximum absorption 
band at wavelength of 352 nm. The CT complex is also confirmed by both FTIR and 1H NMR measurements. The 
stoichiometry of the CT complex is found to be 1:1 ratio by Job and straight line methods between the donor and the 
acceptor. At the optimum reaction conditions, Beer’s law is obeyed in a concentration limit of 2～8 µg mL−1. The relative 
standard deviation is less than 1.5%. The apparent molar absorptivity is determined to be 1.16×104 L mol−1 cm−1 at 352 nm. 
The thermodynamic properties and reaction mechanism of the CT complexation have been discussed. The developed 
method could be applied successfully for the determination of the studied compound in its pharmaceutical dosage form with 
a good precision and accuracy compared to official method as revealed by t- and F-tests. 
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Charge-transfer (CT) complexes are formed by 
interaction between electron donors and electron 
acceptors. CT complexation is important phenomenon 
in biochemical and bioelectrochemical energy transfer 
process. The CT reaction has been widely studied in 
recent years1-4. Many drugs are easy to determine by 
spectrophotometry based on stable CT complexes 
formed. 
Epsilon aminocaproic acid (EACA) (also known as 
6-aminohexanoic acid or epsilcapramin, marketed as
Amicar) is attributed to synthetic amino acid
derivative. It is an anti-fibrinolytic agent that acts by
inhibiting plasminogen activators which have
fibrinolytic properties. It binds reversibly to the
kringle domain of plasminogen and blocks the
binding of plasminogen to fibrin and its activation to
plasmin, which is hydrophilic drug5 used as to reduce
blood loss and transfusion6 after total hip and total
knee arthroplastic surgery7,8 and undergoing open
heart surgery9 and during cranial vault reconstruction
surgery10 and undergoing mitral valve replacement
surgery11. It prevents high glucose and insulin
induced-invasiveness in MDA-MB-231 breast cancer
cells, modulating the plasminogen activator system12.
It can be administered orally or intravenously and is
excreted in the urine.
Several methods have been reported for 
quantitative determination of EACA by Rapid 
chromatographic technique13 and high performance 
liquid chromatographic14 and Gas-chromatographic15 
and reversed-phase chromatography with fluorescence 
detection16 and liquid chromatography-tandem 
mass spectrometry17 and High-Voltage Paper 
Electrophoresis18 and sequential injection analysis19 
and titrimetric5 methods. The titrimetric method is 
laborious, less sensitive and time consuming. The 
chromatographic methods require labor-intensive 
sample preparation procedure and personnel skilled in 
chromatographic techniques. The other methods 
generally require complicated equipment, provision 
for use and disposal of solvents.  
A new spectrophotometric method for 
determination of studied drug was reported in this 
paper, through CT complexation with 2,3,5,6-
tetrabromo-1,4-benzoquinone (bromanil, TBBQ) 
having been satisfactorily applied to the determination 
of this drug in injection pharmaceutical formulation. 
Materials and Methods 
Apparatus 
A Cary 300 UV-visible spectrophotometer (Varian, 
USA) was used for the absorbance measurements, 




using 10 mm path-length quartz cells. The pH was 
measured on a 210 precise acidometer (Hanna, Italy). An 
infrared (IR) spectrometer Nicolet iS5 FT-IR (Thermo 
Scientific, USA) was used to record the spectrum. All 
1H NMR experiments were carried out on a Bruker 
Avance III 600 MHz spectrometer (Bruker, Germany). 
 
Reagents 
All chemicals and solvents used were of analytical 
reagent grade. TBBQ (TCI Development Co. Ltd. 
Japan) was prepared as 1 mg mL−1 in ethanol. The 
drug standard sample of EACA was kindly provided 
by National Drug Group Chemical Reagents Co., Ltd. 
China. The standard drug solution of 100 μg mL−1 
was prepared by dissolving studied standard drug 
sample in water. Borax buffer solution of 0.1 mol L−1 
was prepared by dissolving borax in water. 
 
Pharmaceutical formulation 
The following available commercial preparations 
were analyzed: EACA injections (Xinyijinzhu 
Pharmaceutical Co. Ltd., Shanghai, China), labelled 
to contain 2 g EACA, 10 mL per injection. 
 
General procedure 
A suitable amount of drug solution was pipetted 
into a 10 mL volumetric flask, then 1 mL of TBBQ 
solution and 1.5 mL of borax buffer solution was 
added, and the solution was diluted to volume with 
water and mixed thoroughly. The solution was 
thermostated at 70 °C of water bath for 30 min. After 
rapidly cooling, the absorbency of the CT complex of 
EACA with TBBQ was measured at 352 nm against a 
blank solution. The calibration graph was constructed 
in the same way with the standard drug solution of 
known concentrations. The amount of studied drug 
was computed from corresponding calibration graph. 
 
Analysis of pharmaceutical formulation  
0.5 mL of injection of EACA was transferred into a 
100 mL calibrated flask, the solution was diluted to 
volume with water. The solution 10 mL was again 
diluted up to 100 mL with water. Then the same 
detection as mentioned in the section general 
procedure was used. 
 
Preparation of the complex for IR measurement 
5 mL of 2 mmol L−1 of the drug standard sample of 
EACA in water, as well as 5 mL of 2 mmol L−1 of 
TBBQ in ethanol, was added to a round bottom flask 
and thermostated at 70 °C in water bath for 30 min. 
The solvent was evaporated under reduced pressure 
and the resulting residues were dried over calcium 
chloride for IR measurement. 
Solution for 1H NMR measurements  
5 mg of the drug standard sample of EACA was 
accurately weighed and dissolved in 1 mL of d6-DMSO, 
and 1 mL of solution containing an equimolar amount 
of TBBQ in the same solvent was added. The solution 
was thermostated at 70 °C of water bath for 30 min 
and subjected directly to 1H NMR measurement. 
 
Results and Discussion 
 
Absorption spectra 
The absorption spectrum of the CT reaction 
product between TBBQ and studied drug is shown in 
Fig. 1. The spectrum shows the new maximum 
absorption band at wavelength of 352 nm, which is 
not due to the absorption of any of the reactants and 
considered to be result of CT complex formation 
between the investigated drug and TBBQ. The new, 
low energy absorption observed in solution containing 
both a donor and an acceptor has been described by 
Mulliken20 as CT transition involving the excitation of 
an electron on the donor to an empty orbital on the 
acceptor. This drug can be determined 
colorimetrically by the formation of CT complex with 
TBBQ. The absorbance of the complex was then 
measured at its maximum wavelength. Investigations 
were carried out to establish the most favourable 
conditions for the CT formation. The influence of some 
variables on the reaction has been tested as follows. 
 
Effect of solvent 
Absorption spectral characteristics of the CT 
complex of studied drug with TBBQ in different 
solvents were evaluated. The studied solvents 
involved water, methanol, ethanol, acetone, 
acetonitrile and dimethylsulphoxide. Experimental 
results indicated that a mixed solvent of water–
ethanol was suitable for studied drug as it gave the 
 
 
Fig. 1 — Absorption spectra of (a) EACA/TBBQ and (b) TBBQ
[c(TBBQ) = 100 μg mL−1; c(EACA) = 6 μg mL−1] 
 




maximum and stable absorbance at the ratio of water 
to ethanol being 9:1 (v/v). 
 
Effect of reaction temperature and time 
Effect of reaction temperature on the absorption 
of the CT complex was studied in the range of 20 to 
 80 °C on a water-bath for 0 to 60 min. The suitable 
temperature and time for obtaining maximum and 
stable absorbance were carried out at 70 °C for  
30 min. The stable time of CT complex at room 
temperature is at least 3 h. 
 
Effect of pH of working solution 
The absorption intensity of the CT complex was 
dependent on pH. At pH<5.0 almost no reaction was 
observed, due to the low nucleophilicity of the 
protonated amino-group. At the pH range of 8.5 to 
11.0, the absorption of the complex was most 
intensive in borax buffer solution. The suitable volume 
of borax buffer solution of 0.1 mol L−1 was 1.5 mL.  
 
Effect of TBBQ concentration 
The influence of CT reagent concentration was 
studied in the range 50–300 μg mL−1. Experiment 
indicated that 100 μg mL−1 of TBBQ concentration is 
enough for studied compound. 
 
Investigations on the structure of the CT complex 
TBBQ is attributed to quinone reagent, which is a 
strong π-acceptor, n–π or π–π CT complexes have 
been reported for determination of many 
compounds21,22. Studied drug, attributed to amino acid 
derivative agent, has one electron rich group of 
amino, which may form n–π CT complex with TBBQ 
at the same time. This drug is probably through the 
lone pair of electron donated by the N atom in the 
amino (n-electron donors) to bromanil (π-electron 
acceptor). So, CT complex can be formed with this 
drug. When TBBQ was added to the studied drug 
solution, the drug solution with TBBQ causes a 
change in the absorption spectrum with new 
characteristic band at 352 nm. The appearance of the 
new band was the evidence for the possible CT 
complex formation of the type n-π complex between 
the studied component and TBBQ.  
The formation of the complex was also confirmed 
by IR measurement. The majority of infrared 
measurement on the CT complex has been concerned 
with the shifts in the vibrational frequencies of 
acceptor. Decrease in the vibration frequency of a 
particular band has been used as an evidence for a 
particular site of a CT interaction23. The IR spectra of 
TBBQ (Fig. 2) show strong bands at 1673, 1547 and 
1055 cm−1 corresponding to νC=O, aromatic νC=C and 
νC-Br. These bands were shifted in the spectra of the 
complex with the investigated compound to 1652, 
1534 and 1040 cm−1, respectively. 
In 1H NMR, generally, the protons of the donor are 
shifted to a lower field (paramagnetic shift)21,24. 
Comparison between the chemical shifts in the  
1H NMR spectra (Fig. 3) before and after reaction 
helped in ascertaining the exact binding site of the 
studied drug. The 1H NMR spectrum of the complex 
of the investigated compound with TBBQ was 
measured in d6-DMSO together with the spectrum of 
the free compound. Experimental results indicated 
that in the 1H NMR spectrum of the complexed 
EACA, since only the chemical shift of –CH2 in 
NH2CH2– of EACA molecule was shifted to a lower 
field (∆δ ＝ 0.19), other protons of the complex 
showed no evident changes. This could be explained 
as follows: the unpaired electron on the nitrogen atom 
of the amino-group of EACA transferred to TBBQ, 
which induced a decrease of electron cloud density on 
the proton of –CH2 in NH2CH2– of EACA molecule, 
as a result, a lower field chemical shift occurred. This 
indicated that the complexation binding of TBBQ 
with the nitrogen atom of the amino-group of EACA 
gave rise to the CT complex.  
Stoichiometry of the CT complex was determined 
by Job's method of continuous variations, in which 
master solutions of equimolar concentrations of  
 
 
Fig. 2 — FTIR spectra of (a) TBBQ and (b) the CT complex 
 




the donor and acceptor were used in this experiment, 
and it was found to be 1:1 for the drug with  
TBBQ. Further support has been observed in the 
straight line method which can be used as a 
qualitative mean for the determination of the 
stoichiometry ratio of the donor and acceptor in the 
complex. This ratio is likely to engender owing to the 
presence of the nitrogen atom acting as an electron 
drawing group in the molecule of studied drug. The 
nitrogen atom in amino has more electron density and 
less sterically hindered. So, n–π CT complex was 
formed (Fig. 4). 
 
Investigation of thermodynamic properties of CT reaction 
The association constants for the interaction of the 
compound with TBBQ were estimated according to 
the Benesi-Hildebrand equation (Eqn 1) when the 







[A ] 1 1 1
[D ]A K 
     … (1) 
 
where [A0] and [D0] are the total concentrations of the 
acceptor and donor, respectively, AAD is the 
absorbance of the complex at the λmax, ε
AD the molar 
absorptivity of the complex, and CTK is the association 
constant of the complex (l mol−1). From the previous 
equation, on plotting the values of [A0]/A
AD versus 
1/[D0], straight line was obtained (Fig. 5), from which 
the association constants and correlation coefficient 
were obtained (Table 1). 
ΔG° value of the complex is calculated from Gibbs 
free energy of formation according to the relationship 
(Eqn 2): 
 
CTlnG RT K      … (2) 
 
where ΔG° is Gibbs free energy of the CT complex,  
R the gas constant (8.314 J mol−1 K−1), T the 
 
 
Fig. 3 — 1H NMR spectra of (a) epsilon aminocaproic acid and




Fig. 4 — The structure of amino acid derivative EACA complex
with TBBQ 
 
Table 1 — The association constant of the complex between 
donor and acceptor (70 °C) 
Parameters EACA-TBBQ 
 (nm) 352 
KCT Association constant (1/mol) 7827 
Correlation coefficient (r)  0.9976 




Fig. 5 — The curve of [A0]/A versus 1/[D0] in EACA-TBBQ 
system 




temperature in Kelvin, and KCT (l mol
−1) is the 
formation constant of donor–acceptor complex. The 
parameters thus obtained are represented in Table 1, 
and these value show that complexation is 
thermodynamically favoured. 
 
Calibration graph of EACA 
Under the experimental conditions described, 
standard calibration curve of CT complex for the 
amino acid derivative was constructed by plotting 
absorbency intensity versus concentration. The linear 
regression equation is listed in Table 2. The 
correlation coefficient is 0.99941, indicating good 
linearity. The small value of variance confirmed the 
small degree of scattering of the experimental data 
points around the regression line. 
 
Sample analysis 
The proposed method was applied to the 
determination of EACA in injections. Satisfactory 
results were obtained for this drug. Moreover, to 
check the validity of the proposed method, the 
standard addition method was applied by adding the 
pure drug to the previously analyzed injections. The 
recovery of the drug was calculated by comparing the 
concentration obtained from the mixtures with those 
of the pure drug. Five replicate determinations were 
made (Table 3). The obtained mean values ± S.D. of 
the labelled amounts was 100.6 ± 2.9, the recoveries 
ranged from 97.3 ± 1.6 to 102.1 ± 2.6. In the t- and F-
tests, no significant differences were found between 
the calculated and theoretical values (95% 
confidence) of both the proposed and official 
method5, and this indicated similar precision and 
accuracy between proposed and official method. 
Precision of the proposed method was determined 
in each concentration range, by ten measurements 
carried out on different days within a week of 
different solution of studied drug. Target 
concentrations corresponded to middle values of each 
range. Table 4 gives an R.S.D. (within-day and 
between-day) of solutions of certain concentrations 
determined by using the proposed procedure. 
 
Effect of interfering substances 
The assay result was unaffected by the presence of 
excipients as shown by the excellent recoveries 
obtained when analyzing the drug in presence of 
commonly encountered excipients. As samples 
containing a fixed amount of the studied drug  
(5 μg mL−1) and excipients (50 μg mL−1) were 
measured, no interference was observed from 
commonly used excipients such as starch, lactose, 
glucose, fructose, sucrose, and magnesium stearate. 
This fact indicates good selectivity of the method to 
determine the studied drug both in raw material and in 
their dosage forms. 
 
Conclusions 
The results obtained from the present study 
indicate that n–π charge transfer complex formation 
between the amino acid derivative and TBBQ was 
applied in the spectrophotometric assay of EACA in 
its dosage forms. The proposed method can be used 
for the routine quality control of the pure drug and in 
its dosage forms without fear of interference caused 
by the excipients expected to be present in its dosage 
forms. The method has been also applied successfully 
to the determination of the active constituent in a 
commercial pharmaceutical. The proposed method 
has the advantages of easy operation, high recovery, 
 
Table 2 — Quantitative parameters for the CT complex of  
studied drug with TBBQ 
Parameters EACA-TBBQ 
λmax (nm) 352 
Beer’s law limits (μg mL−1) 2−8 
Intercept on the ordinate (a) 0.07259 
Slope (b) 0.08838 
Molar absorptivity (ε) 
(l mol−1 cm−1) 
1. 16×104 
Correlation coefficient (r) 0.99941 
Sandell sensitivity (μg cm−2) 0.011 
 
Table 3 — Determination of EACA drug in injection using  
TBBQ (n = 5) 
EACA  
drug 
Present method Reference 
method5 
Equivalent nominal 





(%) ± S.D.a 
Injection 
100.6 ± 2.9  
(t, 2.47; F, 4.3) 
99.8 ± 3.5 97.4 ± 1.4  
The tabulated values of t and F at the 95% confidence limit are
t = 2.78 and F = 6.39 











EACA 3 1.9 2.5 
 5 1.6 1.9 
 7 2.5 2.8 
a Average of ten determinations 
 




speed, and minimal use of organic solvent. The 
investigation of real samples revealed the potential  
of the method in pharmaceutical analysis. 
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